Vaccinex Inc (NASDAQ:VCNX) Sees Large Growth in Short Interest

Vaccinex Inc (NASDAQ:VCNX) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 52,200 shares, a growth of 27.3% from the August 15th total of 41,000 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 566,200 shares, the short-interest ratio is presently 0.1 days.

In other Vaccinex news, Director Albert Friedberg purchased 1,126,760 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The shares were acquired at an average cost of $3.55 per share, for a total transaction of $3,999,998.00. Following the completion of the purchase, the director now owns 439,555 shares of the company’s stock, valued at approximately $1,560,420.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 68.60% of the company’s stock.

Separately, Oppenheimer reiterated a “buy” rating and set a $22.00 price objective on shares of Vaccinex in a research note on Monday, August 17th.

VCNX opened at $5.29 on Thursday. The company’s 50 day moving average is $5.60 and its 200-day moving average is $4.56. Vaccinex has a 1-year low of $3.22 and a 1-year high of $12.23. The company has a market cap of $106.30 million, a P/E ratio of -2.97 and a beta of 1.48.

Vaccinex (NASDAQ:VCNX) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.12. On average, equities analysts predict that Vaccinex will post -1.75 earnings per share for the current fiscal year.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.

Read More: What is the market perform rating?

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with's FREE daily email newsletter.